Aprea Therapeutics Inc 2026年季度报告

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 For the quarterly period ended March31,2026 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 Aprea Therapeutics, Inc.(Exact name of registrant as specified in its charter) Not Applicable(Former name, former address and former fiscal year, if changed since last report) Securities registered pursuant to Section12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filingrequirements for the past 90 days.Yes⌧No◻ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit suchfiles).Yes⌧No◻ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or anemerging growth company.See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growthcompany” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any newor revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No⌧ There were 12,382,776 shares of the registrant’s common stock, $0.001 par value, outstanding as of May 13, 2026. Aprea Therapeutics,Inc.Quarterly Report on Form10-QFor the Quarter Ended March31,2026 PARTIFINANCIAL INFORMATION5Item 1. Financial Statements5Item 2. Management’s Discussion and Analysis of Financial Condition and Results ofOperations18Item 3. Quantitative and Qualitative Disclosures About Market Risk29Item 4. Controls and Procedures29 PARTIIOTHER INFORMATION30Item 1. Legal Proceedings30Item 1A. Risk Factors30Item 2. Unregistered Sales of Equity Securities and Use of Proceeds90Item 3. Defaults Upon Senior Securities90Item 4. Mine Safety Disclosures90Item 5. Other Information90Item 6. Exhibits91 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form10-Q includes statements that are, or may be deemed, “forward-lookingstatements.” In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “plans,”“intends,” “may,” “designed,” “would,” “could,” “might,” “will,” “should,” “approximately” or, in eachcase, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. They appear in a number of places throughout this QuarterlyReport on Form10-Q and include statements regarding our current intentions, beliefs, projections,outlook, analyses or current expectations concerning, among other things, our ongoing and plannedclinical trials, including for APR-1051 and ATRN-119, our ongoing and planned development, prospectsfor commercialization, and market uptake of our potential product candidates, the strength and breadth ofour intellectual property, the timing of and our ability to make regulatory filings and obtain and maintainregulatory approvals for our product candidates, the legal and regulatory landscape affecting our business,the extent of clinical utility of our product candidates, particularly in specific patient populations,expectations regarding clinical trial data, our development and validation of manufacturing capabilities,our results of operations, financial condition, liquidity, prospects, growth and strategies, the length of timethat we will be able to continue to fund our operating expenses and capital expenditures, our expectedfinancing needs and sources of financing, the industry in which we operate and the trends that may affectthe industry or us. By their nature, forward-looking statements involve risks and uncertainties because they relate to futureevents, competitive dynamics, and healthcare, regulatory and scientific developments and depend oneconomic circumstances that may or may not occur in the future or may occur on longer or shortertimelines than anticipated. We caution you that forward-looking statements are not guarantees, orpredictive, of future performance and that our actual results of operations, financial condition and liquidity,and the development of the industry in which we operate may differ materially from the forward-lookingstateme